A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of Age
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Sponsors Biohaven Pharmaceuticals; Pfizer
- 26 Apr 2023 Planned End Date changed from 28 Mar 2034 to 29 Apr 2027.
- 26 Apr 2023 Planned primary completion date changed from 28 Mar 2034 to 29 Apr 2027.
- 30 Mar 2023 Planned End Date changed from 2 Sep 2026 to 28 Mar 2034.